MOTS-c drug interactions: what's actually known so far

Last updated 2026-07-25

Does MOTS-c interact with other drugs?

Short answer: nobody has actually tested this in people, so any answer beyond that is inference from mechanism, not a citation to a trial. MOTS-c is a 16-amino acid peptide encoded in the mitochondrial genome, first characterized as a regulator of metabolic homeostasis in mice, where it reduced diet-induced obesity and improved insulin resistance ^[1]. That 2015 Cell Metabolism paper is the foundation almost everything else builds on, and it is a mouse study. No human pharmacokinetic or drug-interaction trial has been published for MOTS-c as of this writing. A 2023 review in Frontiers in Endocrinology calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation" ^[2], which is an honest way to describe where the science sits: promising, not proven, and definitely not characterized for interactions the way an FDA-approved drug would be. You can check any approved drug's official interaction data in Drugs@FDA ^[3]. MOTS-c has no entry there, because it isn't an approved drug. So the interaction question really splits into two parts: what do we know about MOTS-c's biological targets that might overlap with common medications, and what does its unregulated status mean for combining it with anything else. Both matter, and neither has a clean answer yet.

Can MOTS-c be taken with metformin or other diabetes drugs?

This is the most-asked version of the interaction question, because MOTS-c's headline biology is glucose regulation, the same territory metformin, sulfonylureas, and insulin work in. Mechanistically, MOTS-c activates AMPK, the same energy-sensing pathway metformin engages, which is exactly why researchers are excited and exactly why a prescriber should know if you're combining the two. In mice, MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes model ^[4]. A 2025 paper in Experimental & Molecular Medicine found the peptide prevents pancreatic islet cell senescence in a diabetes model, which is a different mechanism than existing oral agents (protecting beta cells rather than just increasing insulin sensitivity or output) ^[5]. A 2023 Metabolites paper titled "MOTS-c Functionally Prevents Metabolic Disorders" adds more rodent-model support for a glucose-lowering effect ^[6], and a 2023 Diabetes & Metabolism Journal review ties MOTS-c to diabetes and aging-related disease broadly ^[7]. None of this is a human dosing study, and none of it tells you what happens if you stack MOTS-c on top of metformin, a GLP-1 drug, or insulin. If MOTS-c does lower blood glucose through an AMPK-linked pathway in humans the way it does in rodents, additive hypoglycemia risk with insulin or sulfonylureas is a reasonable concern to raise with whoever manages your diabetes care, not something to test on yourself by trial and error. Anyone on glucose-lowering medication who is considering MOTS-c should talk to their prescriber first and monitor glucose more closely than usual if they proceed. See our MOTS-c dosage guide for how researchers have approached dosing ranges in the studies published so far.

Does MOTS-c interact with statins or cardiovascular drugs?

There's an emerging cardiovascular thread in the MOTS-c literature, but it's early and it's rodent- and cell-based, not clinical. A 2025 review in Cardiovascular Drugs and Therapy, provocatively titled "MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?", surveys mechanistic work suggesting a protective role in heart tissue under metabolic stress ^[8]. Separately, a 2025 American Journal of Respiratory Cell and Molecular Biology paper found MOTS-c promotes glycolysis via an AMPK-HIF-1α-PFKFB3 pathway to reduce lung injury after cardiopulmonary bypass, in an animal model ^[9]. And a 2025 Redox Biology paper found MOTS-c reduced lung injury after ischemia-reperfusion via a MYH9-dependent mechanism, again in an experimental model ^[10]. What this doesn't tell you: whether MOTS-c changes statin metabolism, whether it interacts with antiplatelet drugs, or whether it's safe alongside blood pressure medication. Nobody has looked. If you have existing cardiovascular disease and are on a drug regimen for it, the honest position is that MOTS-c's cardiac effects are a hypothesis under animal-model investigation, not a known quantity you can safely layer onto a prescribed regimen without your cardiologist knowing.

Is MOTS-c safe to combine with other peptides (like SS-31 or humanin)?

MOTS-c belongs to a small family of mitochondrial-derived peptides, and the family members don't necessarily behave the same way, which matters if you're thinking about stacking them. A 2018 paper in Rejuvenation Research is titled, bluntly, "Mitochondrial-Derived Peptides Exacerbate Senescence" ^[11], a reminder that this peptide class isn't uniformly protective. Some mitochondrial-derived peptides have been linked to worsening cellular aging markers in certain contexts, which cuts against the simple "mitochondrial peptide equals anti-aging" framing you'll see in marketing copy. A 2021 review in Biochimica et Biophysica Acta looked specifically at mitochondrial-derived peptides and exercise physiology ^[12], and a 2022 Diabetes & Metabolism Journal paper covers MOTS-c specifically in the context of exercise-induced mitohormesis ^[3]. These are useful for understanding MOTS-c's proposed mechanism, but they don't address peptide-on-peptide interactions. If you're combining MOTS-c with another research peptide, you're combining two things with no joint safety data, on top of each having thin standalone human data. That's stacking uncertainty on uncertainty, not stacking benefits.

What about MOTS-c and supplements (NAD+ precursors, resveratrol, berberine)

This is one of the biggest gaps in the literature: there is essentially no published data on MOTS-c combined with common longevity supplements. Berberine is worth flagging specifically because it also activates AMPK, the same pathway MOTS-c appears to engage in rodent studies ^[1]. Two AMPK activators taken together is a plausible additive-effect scenario, but "plausible" is not the same as "studied," and nobody has published human or animal data on the combination specifically. NAD+ precursors (NMN, NR) and MOTS-c both get marketed under the broad "mitochondrial health" umbrella, which leads people to assume they're complementary. Mechanistically, MOTS-c's 2018 Cell Metabolism paper showed it translocates to the nucleus under metabolic stress to regulate nuclear gene expression ^[13], which is a distinct mechanism from NAD+ salvage pathways. Distinct mechanism doesn't mean safe combination or synergistic combination. It means untested combination.

What does 'unregulated' actually mean for interaction risk?

This is the part that matters more than any single mechanism paper: MOTS-c is not an FDA-approved drug, and it is not on either FDA bulk drug substance list that governs legal compounding. Compounding pharmacies operating under Section 503A can only use bulk drug substances that appear on the list established under 21 CFR 216.23 ^[14], and outsourcing facilities under 503B work from a separate list under 21 CFR 216.24 ^[15]. FDA's own bulk drug substances page for 503A compounding ^[16] and its current nominated-substances list ^[17] are the places to check what's actually permitted; MOTS-c has been a nominated substance under FDA review rather than an approved bulks-list entry, and that status can change, so check the current list rather than relying on this article to be up to date. What that means practically: there is no FDA-reviewed label, no official interaction data, and no post-market surveillance system flagging adverse events the way there is for approved drugs. The interaction data you'd normally lean on (from a package insert, from Drugs@FDA ^[3], from a pharmacist's drug-interaction database) simply doesn't exist for MOTS-c. A 2026 Sports Medicine review on peptide therapies for musculoskeletal and athletic use makes the same point across the broader unapproved-peptide category: safety and efficacy data lag far behind the marketing ^[18]. That gap is the actual story here, not a footnote to it.

Does MOTS-c interact with muscle, bone, or joint medications?

This is where the animal data is thickest, and where the interaction question gets more specific. MOTS-c has been shown to modulate skeletal muscle function by directly binding and activating CK2, an enzyme with broad roles in cell signaling, in a 2024 iScience paper ^[19]. Separate rodent work found MOTS-c reduces myostatin and muscle atrophy signaling ^[20], promotes muscle differentiation in cell models ^[21], and attenuates immobilization-induced muscle atrophy by suppressing lipid infiltration in a 2024 American Journal of Physiology paper ^[22]. A 2023 Frontiers in Physiology paper reviews MOTS-c's role in bone metabolism ^[23], and a 2025 Free Radical Biology & Medicine paper found MOTS-c reduced cartilage degradation in an osteoarthritis model via an Nrf2-dependent mechanism ^[24]. If you're on a bisphosphonate, an osteoporosis drug, or an anti-inflammatory for joint disease, none of these papers give you interaction data with those specific drug classes. What they do suggest is that MOTS-c's targets (CK2, myostatin signaling, Nrf2 pathways) overlap with pathways some musculoskeletal drugs also touch, which is a reason for caution, not reassurance. See our MOTS-c injection sites page if you're weighing administration logistics against these open questions.

Is the 'exercise mimetic' framing about interactions accurate?

No, and this deserves a direct answer because it shapes how people think about stacking MOTS-c with other things. MOTS-c is often marketed as "exercise in a pill," a phrase that implies it replicates the systemic effects of a workout, interactions and all. The actual research is narrower. A 2022 Diabetes & Metabolism Journal paper on exercise and mitohormesis found MOTS-c rises with exercise and contributes to some of its downstream effects ^[3], and a 2025 Scientific Reports paper found MOTS-c "mimics exercise" specifically in combating diabetic liver fibrosis in a rodent model, through a Keap1-Nrf2-Smad2/3 pathway ^[25]. That's a real, specific mechanistic finding in one disease model. It is not evidence that MOTS-c replicates the full physiological signature of exercise, including whatever interaction profile exercise itself has with your medications. Exercise doesn't interact with drugs the way a chemical does, it changes glucose disposal, blood flow, and drug clearance through physiology. If MOTS-c partially mimics some of those downstream effects, the same caution that applies to starting a new exercise program on insulin or blood pressure medication (checking with your doctor, monitoring more closely at first) reasonably applies here too. Treat the exercise-mimetic language as a description of one mechanism in one study, not a blanket safety claim.

What about MOTS-c and cancer treatment or hormone therapy?

There's a genuinely interesting and genuinely early signal here that's worth knowing, especially if you're on any cancer-related or hormone-modulating regimen. A 2024 paper in Advanced Science found MOTS-c suppressed ovarian cancer progression in a lab model by attenuating USP7-mediated LARS1 deubiquitination ^[26], a specific molecular mechanism, not a demonstrated clinical anti-cancer effect. Separately, a 2024 paper in Gut found MOTS-c has an antiviral role during hepatitis B infection through mitochondrial remodeling ^[27]. These are mechanistically distinct findings in different disease models, and neither has moved to human trials. If you are undergoing cancer treatment or are on hormone therapy, this is exactly the situation where self-directed use of an unapproved peptide with unknown interaction effects is the wrong call. Oncology drug regimens are precisely tuned, often with narrow therapeutic windows, and introducing an unstudied compound without your oncology team's knowledge isn't a reasonable risk to take based on cell-culture and rodent findings, however promising they read.

How should researchers and clinicians think about this evidence gap?

The honest framing: MOTS-c has one of the more mechanistically rich rodent and cell-model literatures of any research peptide right now, touching glucose metabolism ^[1][4], muscle ^{[19][20][21][22]}, bone and cartilage ^[23][24], lung injury ^[9][10][28], fibrosis ^[29][25], and even membrane repair ^[30] and stem cell modulation in disc degeneration models ^[31]. A 2019 BioEssays review frames MOTS-c as a mitochondrial-encoded regulator of the nucleus ^[13], underscoring how broad its proposed reach is. Breadth of mechanism is not the same as depth of safety data. No human interaction study exists. No FDA-reviewed label exists. The MOTS-c evidence hub covers what the core studies actually show and don't show, and how to take MOTS-c peptide covers administration basics researchers reference, but neither can substitute for the interaction data that simply hasn't been generated yet. If you're a researcher or clinician-adjacent reader evaluating whether to use MOTS-c alongside an existing medication regimen, the responsible path is the same one you'd apply to any unapproved compound: loop in the prescriber managing that regimen, disclose the peptide use explicitly, and monitor for the specific interaction risks the mechanism suggests (glucose lowering with diabetes drugs, additive AMPK activation with berberine, unknown effects on a narrow therapeutic-window oncology drug). For sourcing peptide material at all, look for a provider-reviewed route that connects to a named, licensed fulfilling pharmacy rather than an anonymous supplier, since interaction and quality risk compound when you can't verify what's actually in the vial.

Frequently asked questions

Can I take MOTS-c with metformin?

No published human study has tested this combination. Mechanistically both engage AMPK signaling, so additive glucose-lowering is plausible, based on rodent MOTS-c data [PMID 25738459]. Anyone on metformin or another glucose-lowering drug should tell their prescriber before adding MOTS-c and watch for hypoglycemia symptoms if they proceed.

Does MOTS-c interact with insulin?

There's no clinical interaction study. Because rodent research shows MOTS-c improves insulin resistance and lowers glucose [PMID 25738459][PMID 34798268], combining it with exogenous insulin raises a theoretical additive hypoglycemia risk that hasn't been quantified in humans. This combination should only be considered under medical supervision with closer glucose monitoring.

Is MOTS-c safe with statins?

Unknown. MOTS-c has been studied for cardiac and metabolic effects in rodent and cell models [PMID 40172798], but no research has looked at statin co-administration specifically. There's no known mechanistic red flag, but 'no known interaction' here means 'not studied,' not 'confirmed safe.'

Can MOTS-c be combined with other peptides like BPC-157 or SS-31?

No joint safety data exists for MOTS-c stacked with other research peptides. A 2018 Rejuvenation Research paper found some mitochondrial-derived peptides can exacerbate senescence markers in certain contexts [PMID 30058454], a reminder that the peptide family doesn't behave uniformly. Stacking unstudied peptides multiplies unknowns rather than benefits.

Does MOTS-c interact with NAD+ supplements like NMN or NR?

No published data addresses this combination directly. MOTS-c acts through nuclear gene regulation under metabolic stress [PMID 29983246], a different mechanism than NAD+ salvage pathways, but distinct mechanisms don't guarantee a safe or neutral combination, they just mean nobody has tested it together.

Is MOTS-c approved by the FDA?

No. MOTS-c is not an FDA-approved drug and does not appear in the Drugs@FDA database. It has been reviewed as a nominated bulk drug substance for compounding, governed by the 503A and 503B bulks lists under 21 CFR 216.23 and 216.24, but check FDA's current lists directly since status can change.

Can people on diabetes medication safely try MOTS-c?

This should go through a prescriber, not be self-directed. Rodent studies show MOTS-c lowers glucose and improves insulin sensitivity [PMID 25738459][PMID 40855115], which means combining it with any glucose-lowering drug carries a plausible additive risk that hasn't been measured in people. Disclose any peptide use to whoever manages your diabetes care.

Does MOTS-c interact with blood pressure or heart medications?

No dedicated interaction study exists. MOTS-c has shown protective effects in cardiac and lung injury models tied to metabolic stress [PMID 40172798][PMID 40035775], but these are animal and mechanistic findings, not evidence about combining it with antihypertensives, antiplatelets, or other cardiac drugs.

Is MOTS-c risky to combine with cancer treatment?

Treat this combination as one to avoid without oncology team involvement. A 2024 Advanced Science paper found MOTS-c suppressed ovarian cancer progression in a lab model through a specific molecular pathway [PMID 39321430], but that's cell-model evidence, not a clinical finding, and cancer drug regimens have narrow therapeutic windows that shouldn't absorb unstudied variables.

Why is there so little human interaction data on MOTS-c?

MOTS-c research is still concentrated in rodent and cell-culture models across nearly every organ system studied so far, from muscle [PMID 39559755] to lung [PMID 40403491] to liver [PMID 40425777]. Human trials, including interaction studies, typically follow years after strong preclinical signals, and MOTS-c hasn't reached that stage yet.

What should I tell my doctor if I'm considering MOTS-c?

Name the specific compound, the dose and frequency you're considering, and every other medication and supplement you take, especially anything affecting glucose (metformin, insulin, sulfonylureas) or AMPK signaling (berberine). Ask specifically about monitoring, since no formal interaction data exists to guide that conversation otherwise.

Does 'exercise mimetic' mean MOTS-c has the same interaction profile as exercise?

No. That phrase describes one mechanistic finding, that MOTS-c mimics exercise effects in a diabetic liver fibrosis model via a specific pathway [PMID 40425777], not a claim that MOTS-c replicates exercise's full physiological or interaction profile. Exercise itself interacts with insulin and blood pressure drugs through changes in glucose disposal and blood flow; whether MOTS-c does the same hasn't been established in humans.

Sources

1. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in a mouse model
2. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation
3. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model
4. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes in a model system
5. PubMed, Metabolites 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in preclinical research
6. PubMed, Diabetes & Metabolism Journal 2023 (PMID 36824008): Review connects MOTS-c to diabetes and aging-related disease mechanisms
7. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): Review of MOTS-c's proposed protective role in diabetic cardiomyopathy
8. PubMed, American Journal of Respiratory Cell and Molecular Biology 2025 (PMID 40035775): MOTS-c promotes glycolysis via AMPK-HIF-1α-PFKFB3 pathway to reduce cardiopulmonary bypass-induced lung injury in an animal model
9. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via a MYH9-dependent mechanism
10. PubMed, Rejuvenation Research 2018 (PMID 30058454): Some mitochondrial-derived peptides have been found to exacerbate senescence in certain contexts
11. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of mitochondrial-derived peptides and their relationship to exercise physiology
12. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): MOTS-c rises with exercise and is linked to mitohormesis in the exercise-response pathway
13. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
14. eCFR, 21 CFR 216.23: Section 503A compounding pharmacies may only use bulk drug substances on the established bulks list
15. eCFR, 21 CFR 216.24: Section 503B outsourcing facilities operate under a separate bulk drug substances list
16. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA maintains the official page governing which bulk substances are permitted for 503A compounding
17. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): FDA's current nominated substances list is the authoritative place to check MOTS-c's compounding status
18. PubMed, Sports Medicine 2026 (PMID 41966639): Review finds safety and efficacy data lag behind marketing claims across unapproved peptide therapies used for performance
19. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
20. PubMed, American Journal of Physiology 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in research models
21. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
22. PubMed, American Journal of Physiology 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
23. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review covers MOTS-c's role in bone metabolism regulation
24. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c reduces cartilage degradation and pyroptosis in an osteoarthritis model via an Nrf2-dependent mechanism
25. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise effects to combat diabetic liver fibrosis via the Keap1-Nrf2-Smad2/3 pathway in a rodent model
26. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression in a lab model by attenuating USP7-mediated LARS1 deubiquitination
27. PubMed, Gut 2024 (PMID 37788894): MOTS-c has an antiviral role during hepatitis B infection via mitochondrial remodeling
28. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion
29. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c is identified as a potential anti-pulmonary fibrosis factor derived from mitochondria
30. PubMed, Theranostics 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation to the membrane
31. PubMed, Materials Today Bio 2025 (PMID 40510834): MOTS-c-modified hydrogels enhance the activity of nucleus pulposus-derived mesenchymal stem cells in disc degeneration models